Long‐term efficacy and safety of risankizumab for the treatment of moderate‐to‐severe plaque psoriasis: interim analysis of the LIMMitless open‐label extension trial beyond 3 years of follow‐up

Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis

(2020) Andrew Blauvelt et al.   JAMA Dermatology

Efficacy and safety of risankizumab vs. secukinumab in patients with moderate‐to‐severe plaque psoriasis (IMMerge): Results from a phase 3, randomised, open‐label, efficacy assessor‐blinded clinical trial

(2020) R.B. Warren et al.   BRITISH JOURNAL OF DERMATOLOGY

Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the SustaIMM phase 2/3 trial

(2019) Mamitaro Ohtsuki et al.   JOURNAL OF DERMATOLOGY

Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial

(2019) Kristian Reich et al.   LANCET

Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study

(2019) Mark G. Lebwohl et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

Ixekizumab Sustains High Level of Efficacy and Favorable Safety Profile Over 4 Years in Patients With Moderate Psoriasis: Results From UNCOVER‐3 Study

(2019) M G Lebwohl et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials

(2019) Kristian Reich et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study)

(2018) R. Bissonnette et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Shifting the focus - the primary role of IL-23 in psoriasis and other inflammatory disorders

(2018) M.J. Gooderham et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials

(2018) Kenneth B Gordon et al.   LANCET

The role of IL 23 in the treatment of psoriasis

(2017) Lluís Puig   Expert Review of Clinical Immunology

Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis

(2017) Kim A. Papp et al.   NEW ENGLAND JOURNAL OF MEDICINE

The immunogenetics of Psoriasis: A comprehensive review

(2015) Jamie L. Harden et al.   JOURNAL OF AUTOIMMUNITY

Adalimumab treatment optimization for psoriasis: Results of a long-term phase 2/3 Japanese study

(2015) Akihiko Asahina et al.   JOURNAL OF DERMATOLOGY

Selective targeting of the IL23 pathway: Generation and characterization of a novel high-affinity humanized anti-IL23A antibody

(2015) Sanjaya Singh et al.   mAbs

Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: Results from an open-label extension study for patients from REVEAL

(2011) Kenneth Gordon et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY